Alzheimer's Disease Long-term Follow-up… | Clinical Trial

Key information

Conditions

Alzheimer's Disease Alzheimer Disease Brain Diseases Central Nervous System Diseases Dementia Mental Disorders Nervous System Diseases Neurocognitive Disorders Neurodegenerative Diseases Tauopathies

Age range

40 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Bobath Memorial Hospital, Bundang, South Korea

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Men or women aged 40 to 90
Diagnosis of dementia according to DSM-IV
Diagnosis of probable AD as defined by NINCDS-ADRDA criteria
Mild to moderate AD at baseline, as defined by MMSE score of 10 to 26
Patients were generally healthy and ambulatory or ambulatory aided
Patients did not take acetylcholinesterase inhibitor 4 weeks before screening
Patients have useful MRI results 3 months before screening

Exclusion

If they have evidence of TIA or major infarction
Epilepsy patients
If they have evidence of other degenerative or psychiatric disorder, other serious disorder, alcoholism or drug abuse
If they sensitive to acetylcholinesterase
If they taken concomitant medication which were not allowed

Treatment and study plan

Donepezil Hydrochloride

Drug

Primary outcomes

ADAS-cog

Secondary outcomes

MMSE, CDR, GDS, NPI, ADL, SSDQ

Sponsors and collaborators

Lead sponsor

Eisai Korea Inc.

Industry

Registry information

Important dates

Study start: 2004
Primary completion: 2006
Study completion: 2006
First posted: Sep 14, 2005
Registry last updated: Dec 30, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed